Controlled-release morphine bioavailability (MS Contin tablets) in the presence and absence of food
- PMID: 2088996
- DOI: 10.1080/0742-969x.1990.11882681
Controlled-release morphine bioavailability (MS Contin tablets) in the presence and absence of food
Abstract
The bioavailability of a single, orally administered, 30-mg controlled-release morphine tablet (MS Contin Tablet; The Purdue Frederick Company, Norwalk, Conn.) was compared after fasting or a high fat meal in this single dose, randomized, crossover study involving 24 healthy male subjects. There was no significant (p greater than 0.05) difference in the mean extent of morphine absorption over 24 hours in the presence or absence of food (area under the plasma concentration vs. time curve [AUC(0,24)], fed = 107% of fasted). Time to maximal concentration (Tmax) was similar (p greater than 0.05) in the two treatment groups; the mean Tmax for fed volunteers was 2.5 hours versus 2.4 hours for fasted volunteers. The two regimens did not differ significantly (p greater than 0.05) with regard to maximal morphine concentration (Cmax); mean Cmax for fed subjects was 8.22 ng/ml whereas mean Cmax for fasted subjects was 8.53 ng/ It was concluded that consumption of a high fat meal did not affect either the rate or extent of morphine absorption, or any of the other pharmacokinetic parameters tested, following administration of MSC.
Similar articles
-
Sustained relief of chronic pain. Pharmacokinetics of sustained release morphine.Clin Pharmacokinet. 1998 Sep;35(3):173-90. doi: 10.2165/00003088-199835030-00002. Clin Pharmacokinet. 1998. PMID: 9784932 Review.
-
A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine.Adv Ther. 2019 Sep;36(9):2394-2401. doi: 10.1007/s12325-019-01022-4. Epub 2019 Jul 5. Adv Ther. 2019. PMID: 31278694 Free PMC article. Clinical Trial.
-
The United States experience with oral controlled-release morphine (MS Contin tablets). Parts I and II. Review of nine dose titration studies and clinical pharmacology of 15-mg, 30-mg, 60-mg, and 100-mg tablet strengths in normal subjects.Cancer. 1989 Jun 1;63(11 Suppl):2348-54. doi: 10.1002/1097-0142(19890601)63:11<2348::aid-cncr2820631146>3.0.co;2-v. Cancer. 1989. PMID: 2720580
-
Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients.Cancer. 1989 Jun 1;63(11 Suppl):2275-83. doi: 10.1002/1097-0142(19890601)63:11<2275::aid-cncr2820631136>3.0.co;2-4. Cancer. 1989. PMID: 2720576 Clinical Trial.
-
Peak plasma concentrations after oral morphine: a systematic review.J Pain Symptom Manage. 1998 Dec;16(6):388-402. doi: 10.1016/s0885-3924(98)00094-3. J Pain Symptom Manage. 1998. PMID: 9879164
Cited by
-
Sustained relief of chronic pain. Pharmacokinetics of sustained release morphine.Clin Pharmacokinet. 1998 Sep;35(3):173-90. doi: 10.2165/00003088-199835030-00002. Clin Pharmacokinet. 1998. PMID: 9784932 Review.
-
Pharmacokinetics and bioavailability of oxycodone and acetaminophen following single-dose administration of MNK-795, a dual-layer biphasic IR/ER combination formulation, under fed and fasted conditions.Drug Des Devel Ther. 2014 Aug 19;8:1125-34. doi: 10.2147/DDDT.S64261. eCollection 2014. Drug Des Devel Ther. 2014. PMID: 25170252 Free PMC article. Clinical Trial.
-
Effects of food on clinical pharmacokinetics.Clin Pharmacokinet. 1999 Sep;37(3):213-55. doi: 10.2165/00003088-199937030-00003. Clin Pharmacokinet. 1999. PMID: 10511919 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources